The use of nonatigen fish collagen in construction of implants and as drug carriers.
Project goals
For decades, collagen has frequently been used in medicine. The most typical one is bovine collagen that carries known issues such as antigenicity, allergenicity and zoonoses transmission. According to rather limited published data fish collagen seems as a promising alternative. It is believed to be low antigenic, non-allergenic and biologically safer. Further, it likely exhibits depotization effect on drugs, i.e. allows for controlled drug release. The project aim is to systemically, experimentally evaluate chemical, biological, physical and technological properties of select fish collagens, specifically with the respect to its potential use in implants and as a drug carrier. Based on the information gained and vast experience of established interdisciplinary research team in vascular prosthesis design, the novel, safer, nonallergic collagen-treated prosthesis with the capability of predictable drug release will be developed. Other collagen products such as foams and wound dressings will be tested. Significant impact on several areas of biomedical industry is expected.
Keywords
kolagenantigenitadepot lékůcévní náhradycollagenantigenicitydepotization of drugsvascular prothesis
Public support
Provider
Ministry of Health
Programme
Programme to support medical applied research in 2015 to 2022
Call for proposals
Zdravotnický AV 1 (SMZ0201501)
Main participants
Všeobecná fakultní nemocnice v Praze
Contest type
VS - Public tender
Contract ID
15-27941A
Alternative language
Project name in Czech
Využití neantigenního rybího kolagenu při konstrukci implantátů a jako nosiče léků
Annotation in Czech
Kolagen je v medicíně používán už po celá desetiletí. Nejpoužívanější je kolagen bovinní, který má známé nedostatky, jako antigenicitu, alergicitu a přenos zoonóz. Podle publikovaných informací se zdá být slibnou alternativou rybí kolagen. Předpokládá se, že je nízce antigenní, nealergenní a biologicky bezpečnější. Dále má pravděpodobně schopnost depotizace léčiv s možností kontrolovaného uvolňování léčiva . Cílem projektu, je systematicky a experimentálně vyhodnotit chemické, biologické, fyzikální a technologické vlastnosti vybraného rybího kolagenu, především s ohledem na jeho využití při výrobě implantátů a jako nosiče farmak. Na základě znalostí a rozsáhlých zkušeností expertního interdisciplinárního výzkumného týmu, stanoveného pro návrhy v oblasti výroby cévních protéz bude vyvinuta inovativní, bezpečnější, novější a hypoalergenní kolagenová protéza, s možností kontrolovaného uvolňování léčiv. Budou testovány i další výrobky z rybího kolagenu, jako např. pěny a materiály na krytí ran. Tímto projektem očekáváme významný dopad hned na několik odvětví biomedicínského průmyslu
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
FA - Cardiovascular diseases including cardio-surgery
CEP - another secondary branch
FR - Pharmacology and apothecary chemistry
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30104 - Pharmacology and pharmacy
30201 - Cardiac and Cardiovascular systems
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
It is a very high quality project whose objectives have been met in spite of many complications that occurred and called for flexible solution. The obtained results bear the potential for future clinical use in the form of vascular replacements or drug depotisation. Moreover, as a part of the project the new technological procedures have been developed for the production and standardization of the obtained fish collagen and for the measurement of the properties of the knitted fabric used. From the financial point of view, considering the structure and use of particular items, the project fulfilled the tender documents and is in line with both the project proposal and the annual reports. The publication outcomes correlate with the objectives of the project and their number exceeds the number originally declared in the approved project line.
Solution timeline
Realization period - beginning
May 1, 2015
Realization period - end
Dec 31, 2018
Project status
U - Finished project
Latest support payment
Jun 28, 2018
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP19-MZ0-NV-U/01:1
Data delivery date
Jun 28, 2019
Finance
Total approved costs
15,713 thou. CZK
Public financial support
15,713 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK
Basic information
Recognised costs
15 713 CZK thou.
Public support
15 713 CZK thou.
100%
Provider
Ministry of Health
CEP
EI - Biotechnology and bionics
Solution period
01. 05. 2015 - 31. 12. 2018